177 related articles for article (PubMed ID: 35655072)
21. Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
Signorelli D; Ghidotti P; Proto C; Brambilla M; De Toma A; Ferrara R; Galli G; Ganzinelli M; Lo Russo G; Prelaj A; Occhipinti M; Viscardi G; Capizzuto V; Pontis F; Petraroia I; Ferretti AM; Colombo MP; Torri V; Sozzi G; Garassino MC; Jachetti E; Fortunato O
Front Immunol; 2022; 13():987639. PubMed ID: 36203609
[TBL] [Abstract][Full Text] [Related]
22. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease.
Gruss HJ; Hirschstein D; Wright B; Ulrich D; Caligiuri MA; Barcos M; Strockbine L; Armitage RJ; Dower SK
Blood; 1994 Oct; 84(7):2305-14. PubMed ID: 7522624
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer.
Schöne N; Kemper M; Menck K; Evers G; Krekeler C; Schulze AB; Lenz G; Wardelmann E; Binder C; Bleckmann A
J Extracell Vesicles; 2024 Mar; 13(3):e12418. PubMed ID: 38453684
[TBL] [Abstract][Full Text] [Related]
24. Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti-PD-1 and Anti-PD-L1 Treatment in a Checkpoint Refractory Melanoma Model.
Veerman RE; Akpinar GG; Offens A; Steiner L; Larssen P; Lundqvist A; Karlsson MCI; Gabrielsson S
Cancer Immunol Res; 2023 Feb; 11(2):217-227. PubMed ID: 36546872
[TBL] [Abstract][Full Text] [Related]
25. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues.
Gruss HJ; Herrmann F; Gattei V; Gloghini A; Pinto A; Carbone A
Leuk Lymphoma; 1997 Feb; 24(5-6):393-422. PubMed ID: 9086433
[TBL] [Abstract][Full Text] [Related]
26. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma.
Barta SK; Lee JY; Kaplan LD; Noy A; Sparano JA
Cancer; 2012 Aug; 118(16):3977-83. PubMed ID: 22180164
[TBL] [Abstract][Full Text] [Related]
27. Localized Imaging of Programmed Death-Ligand 1 on Individual Tumor-Derived Extracellular Vesicles for Prediction of Immunotherapy Response.
Zhang J; Guan M; Lv M; Liu Y; Zhang H; Zhang Z; Zhang K
ACS Nano; 2023 Oct; 17(20):20120-20134. PubMed ID: 37819165
[TBL] [Abstract][Full Text] [Related]
28. Tumor-derived extracellular vesicles containing microRNA-1290 promote immune escape of cancer cells through the Grhl2/ZEB1/PD-L1 axis in gastric cancer.
Liang Y; Liu Y; Zhang Q; Zhang H; Du J
Transl Res; 2021 May; 231():102-112. PubMed ID: 33321257
[TBL] [Abstract][Full Text] [Related]
29. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
30. Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells: an autocrine anti-apoptotic role.
Voorzanger-Rousselot N; Blay JY
Leuk Lymphoma; 2004 Jun; 45(6):1239-45. PubMed ID: 15360007
[TBL] [Abstract][Full Text] [Related]
31. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
[TBL] [Abstract][Full Text] [Related]
32. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Fas-mediated apoptosis by antigen: implications for lymphomagenesis.
Schattner EJ; Friedman SM; Casali P
Autoimmunity; 2002 Jul; 35(4):283-9. PubMed ID: 12482198
[TBL] [Abstract][Full Text] [Related]
34. Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma.
Yan S; Shang Q; Fan Z; Yang Y; Liu Y; Gao H; Chen K; Liang F; Li X; Zhang Q; Yan H
J Immunol Res; 2022; 2022():5633096. PubMed ID: 36213322
[TBL] [Abstract][Full Text] [Related]
35. Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L.
Ranheim EA; Kipps TJ
Cell Immunol; 1995 Apr; 161(2):226-35. PubMed ID: 7535196
[TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor-alpha and CD40L modulate cell surface morphology and induce aggregation in Ramos Burkitt's lymphoma cells.
Laskov R; Berger N; Scharff MD; Horwitz MS
Leuk Lymphoma; 2006 Mar; 47(3):507-19. PubMed ID: 16523591
[TBL] [Abstract][Full Text] [Related]
37. Programmed death ligand 1 expression in diffuse large B cell lymphoma: correlation with clinicopathological prognostic factors.
Ibrahim EM; Refat S; El-Ashwah S; Fahmi MW; Ibrahiem AT
J Egypt Natl Canc Inst; 2023 May; 35(1):12. PubMed ID: 37150782
[TBL] [Abstract][Full Text] [Related]
38. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
Vari F; Arpon D; Keane C; Hertzberg MS; Talaulikar D; Jain S; Cui Q; Han E; Tobin J; Bird R; Cross D; Hernandez A; Gould C; Birch S; Gandhi MK
Blood; 2018 Apr; 131(16):1809-1819. PubMed ID: 29449276
[TBL] [Abstract][Full Text] [Related]
39. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
Eriksson E; Milenova I; Wenthe J; Moreno R; Alemany R; Loskog A
J Immunol; 2019 Feb; 202(3):787-798. PubMed ID: 30617223
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
